Denali Therapeutics
DNLI
230 hedge funds and large institutions have $1.93B invested in Denali Therapeutics in 2025 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 36 closing their positions.
230% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $630K
31% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 64
25% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 36
4% more funds holding
Funds holding: 222 → 230 (+8)
1.11% more ownership
Funds ownership: 93.6% → 94.71% (+1.1%)
4% more capital invested
Capital invested by funds: $1.85B → $1.93B (+$76.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$45.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$31.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$12.7M |
| 5 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
+$8.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.9M |
| 2 |
BlackRock
New York
|
-$25.1M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$12M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$11M |
| 5 |
Squarepoint
New York
|
-$9.34M |
DNLI Hedge Fund Activity: Q2 2025 in Review
230 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2025, worth a combined $1.93B — up 4.1% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new DNLI positions and 36 closed out — a net gain of 9 holders — while 84 added to existing stakes and 64 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $45.7M. The largest seller was Wellington Management Group, cutting an estimated $80.9M.
- 230 institutional investors held Denali Therapeutics (DNLI) as of Q2 2025, up from 222 in Q1 2025.
- Funds reported $1.93B of Denali Therapeutics stock for Q2 2025, up 4.1% quarter-over-quarter.
- 45 funds opened new Denali Therapeutics positions in Q2 2025 and 36 closed out, a net change of +9 holders.
- The largest Denali Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $45.7M added.
- The largest Denali Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $80.9M sold.
Based on aggregated 13F filings for Q2 2025.